Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 104-Week, Multicenter, Single-Arm, Long-Term, Phase 3 Extension Trial Investigating the Safety and Efficacy of Glepaglutide in Adult Patients With Short Bowel Syndrome (SBS) Completing the EASE SBS 2 Trial

NCT04881825 is registered in ClinicalTrials.gov with Zealand Pharma as lead sponsor.

NCT NCT04881825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04881825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 104-Week, Multicenter, Single-Arm, Long-Term, Phase 3 Extension Trial Investigating the Safety and Efficacy of Glepaglutide in Adult Patients With Short Bowel Syndrome (SBS) Completing the EASE SBS 2 Trial
Lead sponsor
Zealand Pharma
Phase
Phase 3
Overall status
Completed
Start date
June 16, 2021
Completion date
April 30, 2026
Enrollment
84 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

short bowel syndrome